

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7436828

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
JULYUN OH	03/07/2022
HAN XU	03/07/2022
CARL ALEXANDER KAMB	03/07/2022
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	A2 BIOTHERAPEUTICS, INC.
<b>Street Address:</b>	30301 AGOURA ROAD
<b>Internal Address:</b>	SUITE 210
<b>City:</b>	AGOURA HILLS
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	91301
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17663758
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)542-2241
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(617) 542-6000
<b>Email:</b>	IPDocketingBOS@mintz.com
<b>Correspondent Name:</b>	MINTZ LEVIN
<b>Address Line 1:</b>	ONE FINANCIAL CENTER
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02111
<b>ATTORNEY DOCKET NUMBER:</b>	061250-521C01US
<b>NAME OF SUBMITTER:</b>	ANNA MIRÔN
<b>SIGNATURE:</b>	/Anna Mirôn/
<b>DATE SIGNED:</b>	07/18/2022
<b>Total Attachments: 7</b>	
source=_Assignment#page1.tif	
source=_Assignment#page2.tif	
source=_Assignment#page3.tif	

source=\_Assignment#page4.tif

source=\_Assignment#page5.tif

source=\_Assignment#page6.tif

source=\_Assignment#page7.tif

ASSIGNMENT

**Julyun OH, Han XU and Carl Alexander KAMB** each with a mailing address of c/o A2 Biotherapeutics, Inc., 30301 Agoura Road, Suite 210, Agoura Hills, CA 91301 (each referred to as "Assignor") have made an invention(s) (the "Invention(s)") set forth in an application for patent of the United States, entitled **COMPOSITIONS AND METHODS FOR TREATING EGFR POSITIVE CANCERS** and which is a:

- (1)  provisional application
  - (a)  to be filed herewith; or
  - (b)  bearing Application No. , and filed on ;
- (2)  non-provisional application
  - (a)  to be filed herewith; or
  - (b)  bearing Application No. , and filed on ; and/or
- (3)  PCT application
  - (a)  bearing Application No., **PCT/US21/46733** and filed on **August 19, 2021.**

Country	Application No.	Application filing date
US	63/068,249	August 20, 2020
US	63/105,639	October 26, 2020
US	63/230,632	August 06, 2021

**WHEREAS, A2 Biotherapeutics, Inc.**, a corporation having its principal place of business at 30301 Agoura Road, Suite 210, Agoura Hills, CA 91301 its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

**NOW, THEREFORE**, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by

these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the application(s) for patent identified above;
- (c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;
- (d) any application(s) for patent of the United States or other countries claiming the Invention(s);
- (e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any substitute application(s), division(s), continuation(s), and continuation(s)-in-part;
- (f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and
- (g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is the sole and lawful owner of the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.), without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application(s) identified above when known.


The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: 3/7/22

By: 

**Julyun OH**


Witness:

  
Signature

3/7/22  
Date

Lu Ming Wong  
Printed name

Witness:

  
Signature

3/7/22  
Date


Shaina Oaku  
Printed name

Date: 3/7/22

By: 

**Han XU**


Witness:

  
Signature

3/7/2022  
Date

Sharon Oake  
Printed name

Witness:

  
Signature

3/7/2022  
Date

Talar Tokatlion  
Printed name

Date: 3/7/2022

By: C. Alexander

**Carl Alexander KAMB**

Witness:

John Oak  
Signature

3/7/22  
Date

Shauna Oak  
Printed name

Witness:

[Signature]  
Signature


3/7/2022  
Date

Han Xu  
Printed name



For and on behalf of ASSIGNEE:

Date: 03/07/2022

By: 

Name: David Lucas  
Title: Chief Operating Officer  
Company: **A2 Biotherapeutics, Inc.**

Witness:



Signature

3/7/22  
Date

Shane Oahn  
Printed name

Witness:



Signature

3/7/2022  
Date

Aaron Martin  
Printed name